In possible $14 billion ending, Medivation goes back to early days
August 22, 2016 at 02:00 AM EDT
The Big Pharma reportedly set to buy the San Francisco drug developer was an early partner with an unsuccessful Medivation compound.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|